多中心研究:经会阴非靶向系统穿刺在前列腺癌疑似患者中的临床价值
本研究纳入1719例疑似前列腺癌患者,679例接受靶向联合非靶向经会阴系统穿刺;靶向穿刺检出临床显著前列腺癌49%,非靶向穿刺检出20.5%,仅非靶向检出临床显著癌者占1.9%;非靶向穿刺的临床显著癌预测因素包括PSA≥5 ng/ml、PI-RADS 5分和前列腺体积<50 cc。
要点
- 靶向穿刺联合非靶向穿刺时,非靶向穿刺额外检出临床显著癌比例低(1.9%)。
- 非靶向穿刺检出临床显著癌的预测因素:PSA≥5 ng/ml、PI-RADS 5分、前列腺体积<50 cc。
- 靶向穿刺已有临床显著癌者中,非靶向穿刺也检出17.2%的临床显著癌。
核心结论
- 在基于预活检多参数MRI的前列腺癌疑似患者中,仅非靶向经会阴系统穿刺检出临床显著前列腺癌的比例低(1.9%)。
主要发现
- 靶向系统穿刺检出临床显著前列腺癌333例(49%),非靶向系统穿刺检出139例(20.5%)。
- 靶向穿刺有临床显著癌者中,非靶向穿刺也检出117例(17.2%)临床显著癌,另有50例(7.4%)Gleason 3+3。
- 靶向穿刺无任何癌的287例中,非靶向穿刺检出临床显著癌13例(1.9%),Gleason 3+3 18例(2.7%),未检出Gleason >4+3。
关键数值与推荐
- 临床显著前列腺癌定义为主要阈值Gleason 3+4或以上。
- 非靶向系统穿刺检出临床显著癌的预测因素:PSA≥5 ng/ml(OR 2.05,95%CI 1.13-3.73,p=0.02)、PI-RADS 5分(OR 2.26,95%CI 1.51-3.38,p<0.001)、前列腺体积<50 cc(OR 2.47,95%CI 1.57-3.87,p<0.001)。
临床怎么用
- 对于预活检多参数MRI提示PI-RADS 4/5或PI-RADS 3伴PSA密度≥0.12 ng/ml者,靶向联合非靶向系统穿刺时,非靶向穿刺的额外临床显著癌检出率低,可结合预测因素个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The added value of nontargeted systematic prostate biopsies when performed alongside magnetic resonance imaging targeted biopsies in men referred with a suspicion of prostate cancer is unclear. We aimed to determine the clinical utility of transperineal nontargeted systematic prostate biopsies, when performed alongside targeted systematic prostate biopsies, using pre-biopsy multiparametric magnetic resonance imaging. MATERIALS AND METHODS: Consecutive patients referred with a suspicion of prostate cancer (April 2017 to October 2019) underwent pre-biopsy multiparametric magnetic resonance imaging. A transperineal biopsy was advised if multiparametric magnetic resonance imaging PI-RADS® (v.2.0) score was 4 or 5, and score 3 required a prostate specific antigen density 0.12 ng/ml or greater. Primary threshold for clinically significant prostate cancer was defined as any Gleason 3+4 or greater. Multivariable logistic regression analysis identified pre-biopsy predictors of clinically significant prostate cancer in nontargeted systematic prostate biopsies, regardless of targeted pathology (p <0.05, R, version 3.5.1). RESULTS: A total of 1,719 men underwent a pre-biopsy multiparametric magnetic resonance imaging, with 679 (39.5%) proceeding to combined targeted systematic prostate biopsies and nontargeted systematic prostate biopsies. In these men clinically significant prostate cancer was detected in 333 (49%) and 139 (20.5%) with targeted systematic prostate biopsies and nontargeted systematic prostate biopsies, respectively. In those men with clinically significant prostate cancer in targeted systematic prostate biopsies, clinically significant prostate cancer was also present in nontargeted systematic prostate biopsies in 117 (17.2%); Gleason 3+3 was present in 50 (7.4%). In 287 men without any cancer in the targeted systematic prostate biopsies, 13 (1.9%) had clinically significant prostate cancer in nontargeted systematic prostate biopsies. In addition 18/679 (2.7%) had Gleason 3+3 disease and no Gleason greater than 4+3 was detected. Predictors associated with clinically significant prostate cancer in nontargeted systematic prostate biopsies were prostate specific antigen 5 ng/ml or greater (OR 2.05, 95% CI 1.13-3.73, p=0.02), PI-RADS score 5 (OR 2.26, 95% CI 1.51-3.38, p <0.001) and prostate volume less than 50 cc (OR 2.47, 95% CI 1.57-3.87, p <0.001). CONCLUSIONS: Detection of clinically significant prostate cancer in exclusively nontargeted transperineal systematic biopsies in a pre-biopsy multiparametric magnetic resonance imaging pathway was low (1.9%).
引用
- Connor MJ, Eldred-Evans D, van Son M, et al. A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging. J Urol. 2020. PMID: 32516029. doi:10.1097/JU.0000000000001184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。